These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 2407811

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB.
    J Clin Oncol; 2001 Jun 15; 19(12):2983-93. PubMed ID: 11408493
    [Abstract] [Full Text] [Related]

  • 25. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F, Schneider J, Markman M, Reichman BS, Venkatraman E, Barakat R, Almadrones L, Spriggs D.
    Gynecol Oncol; 1997 Oct 15; 67(1):39-45. PubMed ID: 9345354
    [Abstract] [Full Text] [Related]

  • 26. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD, Jones HW, Burnett LS, Johnson DH, Greco FA.
    Am J Clin Oncol; 1990 Oct 15; 13(5):410-5. PubMed ID: 2121019
    [Abstract] [Full Text] [Related]

  • 27. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
    Cocconi G, Bella M, Lottici R, Leonardi F, Ceci G, Passalacqua R, Di Blasio B, Bordi C, Biscottini B, Melpignano M, De Biasi D, Finardi C, Bacchi M.
    Am J Clin Oncol; 1999 Dec 15; 22(6):559-67. PubMed ID: 10597739
    [Abstract] [Full Text] [Related]

  • 28. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 29. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM, Copeland LJ, Kavanagh JJ, Stringer CA, Saul PB, Wharton JT.
    Obstet Gynecol; 1987 Nov 15; 70(5):765-9. PubMed ID: 3658288
    [Abstract] [Full Text] [Related]

  • 30. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H, Hayata T, Terao T, Kawashima Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec 15; 41(12):1936-42. PubMed ID: 2592816
    [Abstract] [Full Text] [Related]

  • 31. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Morris M, Gershenson DM, Burke TW, Kavanagh JJ, Silva EG, Wharton JT.
    Obstet Gynecol; 1990 Dec 15; 76(6):1020-4. PubMed ID: 2234710
    [Abstract] [Full Text] [Related]

  • 32. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
    Martoni A, Tomasi L, Farabegoli G, Fruet F, Pannuti F.
    Cancer Treat Rep; 1984 Nov 15; 68(11):1391-3. PubMed ID: 6594196
    [Abstract] [Full Text] [Related]

  • 33. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK.
    Cancer; 1995 Dec 01; 76(11):2230-6. PubMed ID: 8635025
    [Abstract] [Full Text] [Related]

  • 34. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ, Lele SB.
    Cancer Treat Rep; 1984 Dec 01; 68(12):1433-8. PubMed ID: 6439408
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
    Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F, Guarnieri G, Carollo F, Leonardi V, Meli M, Gebbia N.
    Eur J Gynaecol Oncol; 1993 Dec 01; 14(3):228-33. PubMed ID: 8508880
    [Abstract] [Full Text] [Related]

  • 38. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Strøyer I.
    Gynecol Oncol; 1987 Oct 01; 28(2):161-9. PubMed ID: 3311924
    [Abstract] [Full Text] [Related]

  • 39. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
    Gadducci A, Brunetti I, Bruzzone M, Carnino F, Chiara S, Conte PF, Fioretti P, Foglia G, Ragni N.
    Eur J Gynaecol Oncol; 1992 Oct 01; 13(1 Suppl):36-9. PubMed ID: 1511712
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.